Sulfonylurea action re‐revisited

Sulfonylureas (SU), commonly used in the treatment of type 2 diabetes mellitus (T2DM), stimulate insulin secretion by inhibiting adenosine triphosphate (ATP)‐sensitive K(+) (K(ATP)) channels in pancreatic β‐cells. SU are now known to also activate cyclic adenosine monophosphate (cAMP) sensor Epac2 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Seino, Susumu, Zhang, Chang‐Liang, Shibasaki, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2010
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020675/
https://www.ncbi.nlm.nih.gov/pubmed/24843406
http://dx.doi.org/10.1111/j.2040-1124.2010.00014.x
_version_ 1782316101787451392
author Seino, Susumu
Zhang, Chang‐Liang
Shibasaki, Tadao
author_facet Seino, Susumu
Zhang, Chang‐Liang
Shibasaki, Tadao
author_sort Seino, Susumu
collection PubMed
description Sulfonylureas (SU), commonly used in the treatment of type 2 diabetes mellitus (T2DM), stimulate insulin secretion by inhibiting adenosine triphosphate (ATP)‐sensitive K(+) (K(ATP)) channels in pancreatic β‐cells. SU are now known to also activate cyclic adenosine monophosphate (cAMP) sensor Epac2 (cAMP‐GEFII) to Rap1 signaling, which promotes insulin secretion. The different effects of various SU on Epac2/Rap1 signaling, as well as K(ATP) channels in different tissues, underlie the diverse pancreatic and extra‐pancreatic actions of SU. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2010.00014.x, 2010)
format Online
Article
Text
id pubmed-4020675
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-40206752014-05-19 Sulfonylurea action re‐revisited Seino, Susumu Zhang, Chang‐Liang Shibasaki, Tadao J Diabetes Investig Commentary Sulfonylureas (SU), commonly used in the treatment of type 2 diabetes mellitus (T2DM), stimulate insulin secretion by inhibiting adenosine triphosphate (ATP)‐sensitive K(+) (K(ATP)) channels in pancreatic β‐cells. SU are now known to also activate cyclic adenosine monophosphate (cAMP) sensor Epac2 (cAMP‐GEFII) to Rap1 signaling, which promotes insulin secretion. The different effects of various SU on Epac2/Rap1 signaling, as well as K(ATP) channels in different tissues, underlie the diverse pancreatic and extra‐pancreatic actions of SU. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2010.00014.x, 2010) Blackwell Publishing Ltd 2010-03-25 2010-04-22 /pmc/articles/PMC4020675/ /pubmed/24843406 http://dx.doi.org/10.1111/j.2040-1124.2010.00014.x Text en © 2010 Asian Association for the Study of Diabetes and Blackwell Publishing Asia Pty Ltd
spellingShingle Commentary
Seino, Susumu
Zhang, Chang‐Liang
Shibasaki, Tadao
Sulfonylurea action re‐revisited
title Sulfonylurea action re‐revisited
title_full Sulfonylurea action re‐revisited
title_fullStr Sulfonylurea action re‐revisited
title_full_unstemmed Sulfonylurea action re‐revisited
title_short Sulfonylurea action re‐revisited
title_sort sulfonylurea action re‐revisited
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020675/
https://www.ncbi.nlm.nih.gov/pubmed/24843406
http://dx.doi.org/10.1111/j.2040-1124.2010.00014.x
work_keys_str_mv AT seinosusumu sulfonylureaactionrerevisited
AT zhangchangliang sulfonylureaactionrerevisited
AT shibasakitadao sulfonylureaactionrerevisited

Ejemplares similares